Editor
Finally, there is some good news for drug-resistant strains of tuberculosis (TB). A new therapy protocol has been developed that could work. Results of a ZeNix phase III clinical trial has found that the BPal treatment regimen remains effective against highly drug-resistant strains of tuberculosis with a reduced dosage. “This is going to be a game changer, especially for a high burden country like India,” says Dr Vikas Oswal, member of…
